SCHEMBL24253832

SCHEMBL24253832

O=C1CCCC2(CCN(c3cc(-n4cncn4)ncn3)CC2)N1c1ccc(F)c(F)c1

nearest known ligand 0.33

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HCRTR2 O43614 2/20 0.33
DPP4 P27487 6/20 0.33
CYP11B2 P19099 1/20 0.32
HTR1A P08908 1/20 0.32
DRD2 P14416 1/20 0.32
ADRA1D P25100 1/20 0.32
ADRA1A P35348 1/20 0.32
ADRA1B P35368 1/20 0.32
HCRTR1 O43613 1/20 0.31
KCNH2 Q12809 1/20 0.31
LTC4S Q16873 1/20 0.31
DPP8 Q6V1X1 1/20 0.31
DPP9 Q86TI2 1/20 0.31
WNT1 P04628 1/20 0.30
DYRK1A Q13627 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24253834 0.86 HCRTR1 (0.33) HCRTR2DPP4CYP11B2HTR1ADRD2
SCHEMBL24253540 0.85 HCRTR1 (0.34) HCRTR2DPP4HTR1ADRD2ADRA1D
SCHEMBL24253937 0.85 CYP1A2 (0.35) HCRTR2DPP4HTR1ADRD2ADRA1D
SCHEMBL30424472 0.84 SLC34A1 (0.34) HCRTR2DPP4HCRTR1KCNH2LTC4S
SCHEMBL24253938 0.84 SLC34A1 (0.34) HCRTR2DPP4HCRTR1KCNH2LTC4S
SCHEMBL30423985 0.84 HCRTR1 (0.35) HCRTR2DPP4CYP11B2HTR1ADRD2
SCHEMBL24253866 0.84 HCRTR1 (0.35) HCRTR2DPP4CYP11B2HTR1ADRD2
SCHEMBL30512029 0.83 RPS6KB1 (0.32) HCRTR2CYP11B2HTR1ADRD2ADRA1D
SCHEMBL24253644 0.82 ELOVL1 (0.41) DPP4HTR1ADRD2ADRA1DADRA1A
SCHEMBL30424148 0.82 ELOVL1 (0.41) DPP4HTR1ADRD2ADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4196478-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF Novartis AG (CH) 2023-06-21 EP claimed
CN-116157404-A Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof 诺华股份有限公司 2023-05-23 CN claimed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
EP-4196478-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF Novartis AG (CH) 2023-06-21 EP disclosed
CN-116157404-A Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof 诺华股份有限公司 2023-05-23 CN disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 HCRTR2 3027/4885DPP4 582/4885CYP11B2 22/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 HCRTR2 3027/4885DPP4 582/4885CYP11B2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.